Company Long-Term Loans and Borrowings: vigilneuro.com (VIGL)

Brandmark of vigilneuro.com (VIGL)

The price indicator on the Vigil Neuroscience (VIGL) chart demonstrates long-term debt, which currently stands at 0.01. The business relies on developing treatments for rare brain pathologies, holding exclusive sales rights from the FDA. A stable workforce and the recruitment of specialized executives support project development. However, the risk of failed tests could lead to capital loss in a fierce struggle against industry behemoths.

Vigil Neuro (VIGL) Company Long-Term Liabilities: for the period 07/04/2022 - 08/16/2025

Vigil Neuroscience, Inc. (VIGL) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Price Vigil Neuroscience Inc.|VIGL - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Vigil Neuroscience|VIGL - Total Company Value
- book capitalization information:
Net Asset Value per Share Vigil Neuroscience|VIGL - Company Net Assets|Market Value to Book Value Ratio vigilneuro.com|VIGL - Company Total Assets
- debt level and financial liquidity data:
Total Debt to Capital Coefficient Vigil Neuroscience|VIGL - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Vigil Neuroscience Inc.|VIGL - Company Aggregate Debts|Debts to Net Assets Vigil Neuroscience|VIGL - Company Long-Term Debt|Company Short-Term Debt Vigil Neuroscience|Intermediate Coverage Ratio vigilneuro.com
- earnings and market multiples details:
VIGL - Company Net Income
Summary company analytics:VIGL Vigil Neuroscience
Signature product of Vigil Neuroscience Inc.

Vigil Neuroscience specializes in developing innovative microglia therapies for the treatment of rare neurodegenerative pathologies. This metric aggregates the total volume of all credit obligations with a maturity exceeding one year. Monitoring the company's long-term liabilities allows for an assessment of financial stability and the cost of borrowed capital. Reducing debt minimizes default risks but may limit investments in costly clinical trials. The trend in the company's long-term liabilities reflects the balance between debt load and resources for development.

Competitors of Vigil Neuroscience (VIGL)

Company Long-Term Debts biogen.com BIIB|NBIX - Company Long-Term Debt|Company Long-Term Loans and Borrowings RGC (Regencell Bioscience Ltd)|Axsome Therapeutics Inc (AXSM) - Company Long-Term Debt|Long-Term Debt ACADIA Corp (ACAD)|Company Long-Term Liabilities XENE|Company Long-Term Debt VKTX|Company Long-Term Debts SUPN|Long-Term Debt Volume Catalyst Pharma|Company Long-Term Debts DNLI (Denali Therapeutics Inc)|Long-Term Indebtedness Harmony Corp|Biohaven Ltd. - Company Long-Term Debts|Long-Term Debt Volume amylyx.com AMLX|Trevi Therapeutics, Inc. (TRVI) - Company Long-Term Debt|PRAX (Praxis Precision Medicines Inc) - Company Long-Term Debt|Company Long-Term Liabilities AVXL|CBLL: Company Long-Term Loans and Borrowings|Company Long-Term Debt Prothena (PRTA)|alector.com - Company Long-Term Indebtedness|Company Long-Term Debts ANNX (Annexon)|Omeros Corp (OMER) - Long-Term Debt|NGNE: Company Long-Term Liabilities|ACIU - Company Long-Term Debts|Voyager Therapeutics (VYGR) - Company Long-Term Debt|neumoratx.com - Company Long-Term Loans and Borrowings|Company Long-Term Debt Scilex|Long-Term Debt Tevogen Bio Holdings Inc. TVGN|Company Long-Term Debt Alpha Cognition (ACOG)|Long-Term Debt Volume cogrx.com|Company Long-Term Debts IKT (Inhibikase Therapeutics)|SAVA - Company Long-Term Liabilities|Assertio Therapeutics - Company Long-Term Debts|Long-Term Debt Volume Coya Therapeutics, Inc. COYA|VTGN: Company Long-Term Debts|Long-Term Debt Ovid Therapeutics (OVID)|Company Long-Term Debt Acumen Pharmaceuticals|Company Long-Term Indebtedness CRVO (cervomed.com)|Company Long-Term Debts ATHE|Company Long-Term Liabilities clene.com CLNN|Company Long-Term Debts PEPG (PepGen)|jupiterneurosciences.com (JUNS) - Long-Term Debt|RLMD: Company Long-Term Liabilities|ANVS: Company Long-Term Debt|GRCE: Company Long-Term Debts|AIFF - Long-Term Debt Volume|KLTO (ANEW Medical) - Company Long-Term Debts|NRSN - Long-Term Indebtedness|Company Long-Term Debt Reviva Pharmaceuticals (RVPH)|Company Long-Term Debt MTVA (metaviatx.com)|Company Long-Term Debt NeurAxis NRXS|HSDT: Company Long-Term Indebtedness|Passage Bio Corp - Company Long-Term Debts|Long-Term Debt Neuphoria Therapeutics Inc.|NERV (Minerva Neurosciences) - Company Long-Term Liabilities|athira.com (ATHA) - Company Long-Term Debts|Company Long-Term Debt Addex Therapeutics Ltd|ALZN: Company Long-Term Loans and Borrowings|Company Long-Term Debt Cyclerion Therapeutics (CYCN)|PTIX - Long-Term Debt|Pasithea Therapeutics Corp. - Company Long-Term Liabilities|Cortigent Inc - Company Long-Term Debt|Avenue Therapeutics, Inc. - Company Long-Term Debts|Long-Term Debt Volume Brainstorm Cell Therapeutics Inc. BCLI|CARA: Company Long-Term Debts|Long-Term Indebtedness Chromocell CHRO|ELYM (Eliem Therapeutics, Inc.) - Company Long-Term Debts|Intra-Cellular (ITCI) - Long-Term Debt Volume|Company Long-Term Debt Longboard Pharmaceuticals, Inc. (LBPH)|Company Long-Term Debt MRNS (Marinus Pharmaceuticals Inc)|NKGen - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings NRBO|SAGE - Company Long-Term Debt|SNPX (synaptogen.com) - Company Long-Term Indebtedness|TRVN: Company Long-Term Debts|Long-Term Debt Anew Medical Inc. (WENA)|Company Long-Term Liabilities CERE